Zhang Yiyan, Zhang Xintong, Xu Xiangbo, Guo Xiaozhong, Xu Shixue, Ma Shaoze, Chen Jihong, Qi Xingshun
Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China.
Postgraduate College, China Medical University, Shenyang, China.
Front Med (Lausanne). 2023 Aug 31;10:1228636. doi: 10.3389/fmed.2023.1228636. eCollection 2023.
Hepatitis B virus (HBV) infection is the most common cause of liver cirrhosis. Portal venous system thrombosis (PVST) is a major complication of liver cirrhosis. Recently, it has been shown that C-type lectin-like receptor 2 (CLEC-2) and galectin-1 participate in the activation and aggregation of platelets, thereby promoting the development of thrombosis. This cross-sectional study aims to evaluate the association of serum CLEC-2 and galectin-1 levels with PVST in patients with HBV-related liver cirrhosis.
Overall, 65 patients with HBV-related liver cirrhosis were included, of whom 23 had PVST and 42 did not have. Serum CLEC-2 and galectin-1 levels were measured using enzyme-linked immunosorbent assay kits. PVST was assessed by contrast-enhanced computed tomography and/or magnetic resonance imaging scans. Subgroup analyses were conducted according to the degree and location of PVST.
Patients with PVST had significantly higher serum CLEC-2 ( = 0.006) and galectin-1 ( = 0.009) levels than those without. Patients with partial/complete PVST or fibrotic cord ( = 0.007; = 0.002), but not those with mural PVST ( = 0.199; = 0.797), had significantly higher serum CLEC-2 and galectin-1 levels than those without PVST. Patients with superior mesenteric vein thrombosis had significantly higher serum CLEC-2 ( = 0.013) and galectin-1 ( = 0.025) levels than those without PVST. Patients with main portal vein thrombosis had higher serum CLEC-2 ( = 0.020) and galectin-1 ( = 0.066) levels than those without PVST, but the difference in serum galectin-1 level was not significant between them.
Serum CLEC-2 and galectin-1 levels may be associated with the presence of PVST in HBV-related cirrhotic patients, but this association should be dependent upon the degree of PVST.
乙型肝炎病毒（HBV）感染是肝硬化最常见的病因。门静脉系统血栓形成（PVST）是肝硬化的主要并发症。最近的研究表明，C型凝集素样受体2（CLEC-2）和半乳糖凝集素-1参与血小板的激活和聚集，从而促进血栓形成。本横断面研究旨在评估血清CLEC-2和半乳糖凝集素-1水平与HBV相关肝硬化患者PVST的相关性。
共纳入65例HBV相关肝硬化患者，其中23例发生PVST，42例未发生。采用酶联免疫吸附试验试剂盒检测血清CLEC-2和半乳糖凝集素-1水平。通过增强CT和/或磁共振成像扫描评估PVST。根据PVST的程度和部位进行亚组分析。
发生PVST的患者血清CLEC-2（P = 0.006）和半乳糖凝集素-1（P = 0.009）水平显著高于未发生PVST者。部分/完全PVST或纤维条索形成的患者（P = 0.007；P = 0.002）血清CLEC-2和半乳糖凝集素-1水平显著高于未发生PVST者，而壁内PVST患者（P = 0.199；P = 0.797）与未发生PVST者相比无显著差异。肠系膜上静脉血栓形成的患者血清CLEC-2（P = 0.013）和半乳糖凝集素-1（P = 0.025）水平显著高于未发生PVST者。门静脉主干血栓形成的患者血清CLEC-2（P = 0.020）和半乳糖凝集素-1（P = 0.066）水平高于未发生PVST者，但两者血清半乳糖凝集素-1水平差异无统计学意义。
血清CLEC-2和半乳糖凝集素-1水平可能与HBV相关肝硬化患者PVST的发生有关，但这种相关性可能取决于PVST的程度。
